The Eatl-001 Trial: Results of a Phase 2 Study of Brentuximab Vedotin and CHP Followed By Consolidation with High-Dose Therapy - Autologous Stem-Cell Transplantation (HDT-ASCT) in the Frontline Treatment of Patients with Enteropathy-Associated T-Cell Lymphoma
David Sibon(Hôpital Necker-Enfants Malades), Olivier Hermine(Centre National de la Recherche Scientifique), Adrien Chauchet(Centre Hospitalier Universitaire de Besançon), Guillaume Cartron(Hôpital Saint Eloi), Julie Bruneau(Délégation Paris 5), Shérine Khater(Hôpital Européen Georges-Pompidou), Christophe Cellier(Assistance Publique – Hôpitaux de Paris), Vahid Asnafi(Hôpital Necker-Enfants Malades), Franck Morschhauser(Hôpital Claude Huriez), Anne‐Cécile Gauchy(Centre Hospitalier Universitaire de Reims), Ludovic Lhermitte(Hôpital Necker-Enfants Malades), Elizabeth Macintyre(Inserm), Baptiste Pérard(Centre Hospitalier de la Côte Basque), Georgia Malamut(Délégation Paris 5), Thierry Jo Molina(Hôpital Necker-Enfants Malades), Véronique Morel(Sorbonne Université), Nadine Cerf–Bensussan(Université Paris Cité), Jean-Michel Boulet, Chantal Brouzes
Cited by 17
Related Papers
<i>LMO2</i> -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
|Science|2003|3.5k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
|Journal of Clinical Investigation|2008|1.8k